Patents by Inventor Urvi J. Desai

Urvi J. Desai has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Methods and compositions for treatment of diabetes and related conditions via gene therapy
    Patent number: 6608038
    Abstract: Disclosed are methods and compositions for treatment of diabetes, obesity and diabetic-related conditions. The methods include gene therapy based administration of a therapeutically effective amount of vectors encoding the following: glucokinase regulatory protein alone or co-administered with glucokinase or with metabolism modifying proteins; glucokinase co-administered with metabolism modifying proteins; or glucokinase regulatory protein co-administered with glucokinase in combination with metabolism modifying proteins, to a diabetic patient. Wherein the metabolism modifying proteins include UCP2, UCP3, PPAR&agr;, OB-Rb, GLP-1 and GLP-1 analogs (administered via vector or directly as a peptide). Preferred examples of GLP-1 analogs include GLP-1-Gly8, Extendin-4 and the “Black Widow” chimeric GLP-1 analog. Additionally, PPAR&agr; ligands and DPP-IV inhibitors may be co-administered with the above.
    Type: Grant
    Filed: March 14, 2001
    Date of Patent: August 19, 2003
    Assignee: Novartis AG
    Inventors: Shari L. Caplan, Brian R. Boettcher, Eric D. Slosberg, Sheila Connelly, Michael Kaleko, Urvi J. Desai
  • Methods and compositions for treatment of diabetes and related conditions via gene therapy
    Publication number: 20020065239
    Abstract: Disclosed are methods and compositions for treatment of diabetes, obesity and diabetic-related conditions. The methods include gene therapy based administration of a therapeutically effective amount of vectors encoding the following: glucokinase regulatory protein alone or co-administered with glucokinase or with metabolism modifying proteins; glucokinase co-administered with metabolism modifying proteins; or glucokinase regulatory protein co-administered with glucokinase in combination with metabolism modifying proteins, to a diabetic patient. Wherein the metabolism modifying proteins include UCP2, UCP3, PPAR&agr;, OB-Rb, GLP-1 and GLP-1 analogs (administered via vector or directly as a peptide). Preferred examples of GLP-1 analogs include GLP-1-Gly8, Extendin-4 and the “Black Widow” chimeric GLP-1 analog. Additionally, PPAR&agr; ligands and DPP-IV inhibitors may be co-administered with the above.
    Type: Application
    Filed: March 14, 2001
    Publication date: May 30, 2002
    Inventors: Shari L. Caplan, Brian R. Boettcher, Eric D. Slosberg, Sheila Connelly, Michael Kaleko, Urvi J. Desai